



## Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

August 4, 2020

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 4, 2020-- [Aldeyra Therapeutics, Inc.](https://www.aldeyra.com) (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August:

- **BTIG Virtual Biotechnology Conference 2020**  
Presentation Date: Tuesday, August 11, 2020  
Time: 11:30 a.m. ET
- **2020 Wedbush PacGrow Healthcare Virtual Conference**  
Presentation Date: Wednesday, August 12, 2020  
Time: 12:35 p.m. ET

A live webcast of these presentations will be available on the investor relations page of the company's corporate website at <https://ir.aldeyra.com>. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

### **About Aldeyra Therapeutics**

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit <https://www.aldeyra.com/> and follow us on [LinkedIn](#), [Facebook](#), and [Twitter](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200804005249/en/): <https://www.businesswire.com/news/home/20200804005249/en/>

### **Corporate Contact:**

David McMullin  
Aldeyra Therapeutics, Inc.  
Tel: 781-761-4904 ext. 218  
[dmcullin@aldeyra.com](mailto:dmcullin@aldeyra.com)

### **Investor & Media Contact:**

Scott Solomon  
Sharon Merrill Associates, Inc.  
Tel: 617-542-5300  
[ALDX@investorrelations.com](mailto:ALDX@investorrelations.com)

Source: Aldeyra Therapeutics, Inc.